Blood Cancer United Acquires Drug Supply to Preserve Access for Children With Rare Leukemia (Citybizlist) - Jun 11, 2026 - "The Washington, D.C.-based nonprofit, formerly known as The Leukemia & Lymphoma Society, announced it has secured both the existing inventory of luveltamab tazevibulin and the rights necessary to provide the treatment through the FDA’s compassionate use pathway for children diagnosed with CBFA2T3-GLIS2-rearranged AML....Blood Cancer United stepped in to preserve access to the remaining drug supply at no cost to patients. The organization emphasized that it does not intend to commercialize the therapy and that its role is limited to maintaining availability while broader efforts continue to support research and regulatory pathways for rare pediatric cancers."
Commercial • Acute Myelogenous Leukemia
|